Press Release Immunomic Therapeutics, Inc. 9290 Gaither Road Gaithersburg, MD 20877
January 12, 2007 Ph: 240-731-5232 Fax: 240-597-4061 info@immunomictherapeutics.com www.immunomix.com
FOR IMMEDIATE RELEASE: January 12, 2007 (Gaithersburg, MD)
Immunomic Therapeutics Selected to Present at Mid-Atlantic Diamond Ventures Event. Gaithersburg, MD, January 12, 2007 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that the Company has been selected to present at the Mid-Atlantic Diamond State Venture Conference to be held on February 9, 2007 at the Waterfront Technology Center in Camden, N.J. Quarterly, Mid-Atlantic Diamond Ventures holds venture presentations to showcase high-growth businesses to the investment community. Companies selected to present at the venture panels are first screened through an application and intensive "scrub session" process by MADV's steering committee, which is comprised of executive leaders and successful entrepreneurs with extensive corporate and entrepreneurial experience. Companies presenting in MADV's Venture Forums have proven business models, achieved some revenues, and have well thought-out strategies to rapidly expand their businesses. Mid-Atlantic Diamond Ventures events are open to the public, including the investment and venture capital community, entrepreneurial companies, service providers, and MADV sponsors and affiliates. Additional information about the event can be found on their website at http://sbm.temple.edu/madv. Dr. Bill Hearl, President & CEO of Immunomic Therapeutics said, “I am very pleased and excited to have been selected by the steering committee for the February event. They provided some excellent guidance in advance of the meeting and we are looking forward to a very successful presentation of the Company.” About Mid-Atlantic Diamond Ventures Mid-Atlantic Diamond Ventures (MADV) is a science and high technology business cultivator that provides support to early-stage high technology businesses throughout the Mid-Atlantic region. The cultivator encourages and assists entrepreneurs with innovative scientific ideas or commercially viable technology to start and grow their companies into successful, sustainable technology businesses. Formerly known as Diamond State Ventures, MADV is now an affiliate of the Innovation and Entrepreneurship Institute at Temple University's Fox School of Business. About Immunomic Therapeutics Immunomic Therapeutics was founded in 2005 as a joint effort between Capital Genomix, Inc. and Johns Hopkins University to commercialize the LAMP Technology for cancer, infectious disease and other targets. The core technology is based on the research efforts of Dr. J. Thomas August that began in the mid-1990’s studying intracellular molecular trafficking in dendritic cells. LAMP was found to locate within the cell in the same compartment as the Major Histocompatibility Complex – type II (MHC-II). It was shown that an antigenic protein linked to LAMP would also migrate to the MHC-II compartment. This observation had important ramifications to the development of DNA-based vaccines and Dr. August and JHU were awarded a patent in 1997 for the application of LAMP to genetic vaccines. More recent research has led to the filing of additional patents covering improvements and enhancements for DNA – based vaccines. Immunomic Therapeutics, Inc. (“ITI”) is a privately held biotechnology company headquartered in Gaithersburg, Maryland that is commercializing a portfolio of clinical applications based on “LAMP” vaccine technology. ITI offers access to LAMP – based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.
Iti_pr_6